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Abstract
Ablation of glycosylated lysosomal membrane protein (GLMP, formerly known as NCU-G1)
has been shown to cause chronic liver injury which progresses into liver fibrosis in mice.
Both lysosomal dysfunction and chronic liver injury can cause metabolic dysregulation.
Glmpgt/gtmice (formerly known as Ncu-g1gt/gtmice) were studied between 3 weeks and 9
months of age. Body weight gain and feed efficiency ofGlmpgt/gtmice were comparable to
wild type siblings, only at the age of 9 months the Glmpgt/gt siblings had significantly re-
duced body weight. Reduced size of epididymal fat pads was accompanied by hepatosple-
nomegaly inGlmpgt/gtmice. Blood analysis revealed reduced levels of blood glucose,
circulating triacylglycerol and non-esterified fatty acids inGlmpgt/gtmice. Increased flux of
glucose, increased de novo lipogenesis and lipid accumulation were detected inGlmpgt/gt
primary hepatocytes, as well as elevated triacylglycerol levels inGlmpgt/gt liver homoge-
nates, compared to hepatocytes and liver from wild type mice. Gene expression analysis
showed an increased expression of genes involved in fatty acid uptake and lipogenesis in
Glmpgt/gt liver compared to wild type. Our findings are in agreement with the metabolic alter-
ations observed in other mouse models lacking lysosomal proteins, and with alterations
characteristic for advanced chronic liver injury.
Introduction
Glycosylated lysosomal membrane protein (GLMP, formerly known as NCU-G1) was first de-
scribed as a nuclear protein, capable of regulating gene transcription [1]. Later studies identi-
fied GLMP as a bona fide lysosomal membrane protein [2–4]. The biological function of
GLMP is unknown, but a high degree of conservation of the amino acid sequence indicates an
important function [1]. Recently, we created and characterized a novel mouse model with no
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detectable expression of GLMP (Glmpgt/gt mouse, formerly known as Ncu-g1gt/gt mouse), and
showed that the predominant phenotype is chronic liver injury which had developed into a
well-established fibrosis by the age of 6 months [5]. Further analyses identified accumulation
of iron in Kupffer cells [5], which has been shown to be associated with metabolic dysregula-
tion [6]. Specific accumulation of iron in Kupffer cells has been shown to correlate with the se-
verity of metabolic liver injury [7].
Lysosomal disorders are a group of congenital metabolic disorders caused by malfunction-
ing of a protein related to normal lysosomal function [8–13]. Most lysosomal disorders are
characterized by impaired turnover of certain metabolites, which accumulate intralysosomally
and affect normal lysosome and lysosome-related processes, such as autophagy [9–11]. Defec-
tive recycling of macromolecules through lysosomal pathways may cause insufficient recycling
of metabolites and metabolic stress [11]. In fact, metabolic irregularities have been demonstrat-
ed in several mouse models with lysosomal disorders [14].
Liver fibrosis is a result of chronic liver injury, and is characterized by capillarization of si-
nusoids and redirection of blood directly from the portal tract to the hepatic vein [15–17]. The
impaired perfusion of the liver and loss of fenestrations across the endothelial cell layer con-
tribute to the imbalance in metabolite exchange between plasma and the liver [15]. The liver is
also an important organ for regulation of glucose, lipid and protein metabolism, and chronic
liver injury is known to cause alterations to glucose and lipid homeostasis [18].
Using the Glmpgt/gt mouse, a mouse model lacking this lysosomal membrane protein, and
characterized by chronic liver injury and liver fibrosis, we assessed the metabolic consequences
of GLMP ablation, focusing on liver.
Materials and Methods
Materials
[1-14C]oleic acid (58.2 mCi/mmol), D-[14C(U)]glucose (2.9 mCi/mmol) and [1-14C]acetic acid
(56.0 mCi/mmol) were from PerkinElmer NEN (Boston, MA, US). Dulbecco's Modified Eagle
Medium (DMEM), fetal bovine serum (FBS), Penicillin-Streptomycin (Pen-Strep), Fungizone
and Dulbecco's phosphate-buffered saline (DPBS, with Mg2+ and Ca2+) were purchased from
Life-Technologies (Carlsbad, CA, US). HEPES, L-carnitine, oleic acid (OA), glucose, bovine
serum albumin (BSA), Triton X-100, sodium dodecyl sulfate (SDS) and protease inhibitor
cocktail were from Sigma-Aldrich (St. Louis, MO, US). Sodium chloride and Tris Base were
from VWR (Radnor, PA, US). Corning CellBIND tissue culture plates (12-well and 96-well
plates) were obtained from Corning Life-Sciences (Schiphol-Rijk, The Netherlands). OptiPhase
Supermix and UniFilter-96 GF/B were obtained from PerkinElmer (Shelton, CT, US). Thin
layer chromatography plates were purchased fromMerck (Darmstadt, Germany). Accu-Chek
Aviva Nano Blood Glucose Meter System was purchased from Roche Applied Science (Mann-
heim, Germany). RNeasy Plus kit was obtained from Qiagen (Hilden, Germany). Brilliant III
Ultra Fast SYBR Green qPCRMaster Mix was obtained from Agilent Technologies (Santa
Clara, CA, US) and LightCycler 480 SYBR Green I Master Mix was purchased from Roche Ap-
plied Science. Primers were designed and purchased from DNA Technology (Risskov, Den-
mark) and Life Technologies. Hypnorm was from VetaPharma (Leeds, UK). Midazolam was
from Actavis (Parsippany, NJ, US). Animal diets were purchased from Scanbur (Karlslunde,
Denmark). Protein assay reagent was purchased from Bio-Rad (Bio-Rad, Hercules, CA, US)
and the content of proteins was determined using the Coomassie reagent [19]. All other chemi-
cals used in this study were of standard commercial high-purity quality.
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Animal experiments
All animal experiments were reviewed and approved by the Norwegian Animal Research Au-
thority, and performed according to national laws and regulations. Wild type (WT) and
Glmpgt/gt mice [5] were housed in an approved animal facility with access to standard rodent
chow and water ad libitum unless otherwise stated. Mice were 3 weeks old at the beginning of
the feeding experiment. The body weight and food intake of a total of 27 male WT and 31
male Glmpgt/gt mice, housed in 12 different cages, and a total of 13 female WT and 20 female
Glmpgt/gt mice, housed in 7 different cages were monitored at intervals of 7 days for 12 weeks,
and then at 2, 3.5, 4.5, 6, 7.5 and 9 months of age. Feed efficiency was calculated as the ratio be-
tween body weight gain/week for each individual mouse and the average feed intake/mouse. Bi-
ological samples were collected at designated age points (1, 2, 3.5, 6, 7.5, and 9 months). Blood
was obtained from randomly fed mice through cardiac puncture, and sera were collected after
coagulation and centrifugation at 1500 x g for 20 minutes. Liver, spleen and epididymal fat
pads (representing visceral adipose tissue) were dissected at selected time points, weighed and
frozen in liquid nitrogen. The axillary and inguinal fat depots (representing subcutaneous adi-
pose tissue) and interscapular brown adipose tissue were inspected at 1 and 4.5 months of age.
All biological samples were stored at -80°C until further analysis.
Resting blood glucose and serum and liver lipid levels
Resting blood glucose levels were measured in male WT and Glmpgt/gt mice (age = 5 months)
fed ad libitum using Accu-Chek Aviva Nano Blood Glucose Meter System. Serum levels of
non-esterified fatty acids (NEFA) were analyzed using NEFA-kit according to the supplier´s
protocol (ILS Laboratories Scandinavia AS, Oslo, Norway). Triacylglycerol (TAG) was quanti-
fied in serum and whole liver homogenates using TG PAP 150-kit (BioMerieux, Marcy l’Etoile,
France) according to the supplier’s protocol.
Isolation of primary hepatocytes
Isolation of primary hepatocytes fromWT and Glmpgt/gt mice (age = 4–5 weeks) was carried
out by a two-step perfusion method as described [20]. Liver parenchymal and non-parenchy-
mal cells were separated by differential centrifugation as described elsewhere [21]. Primary he-
patocyte preparations with high viability (> 95%) were used in further studies.
Uptake and oxidation of oleic acid and glucose
Determination of [14C]oleic acid (OA) or [14C]glucose uptake and oxidation has been de-
scribed previously [22]. Primary hepatocytes were isolated as described above, and cultured in
hepatocyte growth medium (DMEM high glucose, enriched with 20% FBS, Pen-Strep and Fun-
gizone) on a 96-well microplate (80.000 cells/well) (Corning CellBIND). For measurements of
OA or glucose uptake and oxidation, the growth medium was removed after 24 h and the cells
were exposed to [14C]OA (0.5 μCi/mL, 100 μM) bound to BSA (40 μM) at a ratio of 2.5:1 in
DPBS (with Mg2+ and Ca2+) with HEPES (10 mM), L-carnitine (1 mM) for 4 h or [14C]glucose
(0.6 μCi/mL, 200 μM) in DPBS (with Mg2+ and Ca2+) with HEPES (10 mM), L-carnitine (1
mM) and BSA (7.2 μM) for 4 h. [14C]CO2 production and total uptake of OA or glucose (sum
of CO2 and cell-associated radioactivity) were calculated using cell protein levels for standardi-
zation as described previously [22].
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Thin layer chromatography
Primary hepatocytes were isolated as described above, and cultured in hepatocyte growth me-
dium in 12-well microplates (200.000 cells/well) (Corning CellBIND). The growth medium
was removed after 24 h and the cells were exposed either to fatty acid medium, consisting of
[14C]OA (0.5 μCi/mL, 100 μM) bound to BSA (40 μM) at a ratio of 2.5:1 in DPBS with HEPES
(10 mM) and L-carnitine (1 mM) for 4 h, or to lipogenesis medium, consisting of [14C]acetate
(0.5 μCi/mL, 100 μM) in DMEM enriched with glucose (5.5 mM) and BSA (10 μM) for 4 h.
The media were collected and stored at -20°C until further analysis, and the remaining cells
washed 3x with PBS before adding 250 μL H2O for cell lysis and solubilized cells were stored at
-20°C. Cell-associated lipids were extracted with chloroform:methanol according to Folch et al.
[23] and separated by thin layer chromatography as previously described [23]. The content of
radiolabelled lipids was normalized against cell protein content.
Analysis of gene expression
RNA extractions from mouse liver were carried out according to the manufacturer using
RNeasy Plus kit. The expression of selected mRNA transcripts (S1 Table) was analyzed by
qPCR using a LightCycler 480 (Roche Diagnostics, Manheim, Germany). PCR efficiencies
were experimentally determined for each primer pair. Relative gene expression was calculated
using the ΔΔCt-method, with Beta-actin and Eukaryotic translation elongation factor 2 as
reference genes.
Western blotting
Tritosomes from liver and kidneys fromWT and Glmpgt/gt mice were isolated as described else-
where [3]. Tritosome preparations (6 μg protein) were electrophoresed on NuPAGE 4–12%
Bis-Tris Mini Gels (Life Technologies), and transferred onto PVDF membranes (Bio-Rad, Her-
cules, CA, USA). After blocking, membranes were incubated overnight at 4°C with rabbit anti-
GLMP serum [3] or rabbit anti-LAMP1 (1:1000, C54H11, Cell Signaling, Beverly, MA, US).
This was followed by 1 h incubation with goat anti-rabbit secondary antibody conjugated to
horseradish peroxidase (1:4000, 65–6120, Life Technologies).
Statistical methods
All results are expressed as mean ± SEM. Linear mixed models (LMM) were used to analyze
overall differences in liver/body weight ratio, spleen/body weight ratio, serum TAG and serum
NEFA levels, using IBM SPSS software (SPSS Inc. Chicago, IL, US). Other data were analyzed
using two-tailed T-test (SigmaPlot, Systat Software Inc, Chicago, IL, US).
Results
Confirmation of GLMP ablation inGlmpgt/gtmice
In agreement with our previous report, analysis of lysosome-enriched fractions from mouse
liver and kidneys after tyloxapol treatment [3] confirmed the lack of GLMP expression in
Glmpgt/gt mice (S1 Fig).
Similar body weight gain and feed intake in WT andGlmpgt/gtmice
Development of body weight in wild type (WT) and Glmpgt/gt mice was monitored from 3
weeks of age. As shown in Fig 1A, the body weight gains were similar for male WT and
Glmpgt/gt mice up to the age of 7.5 months, but the Glmpgt/gt siblings were outgrown by WT
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mice at the age of 9 months. The feed efficiency was indistinguishable between the genotypes
up to the age of 14 weeks (Fig 1B). Similar data were also obtained for female mice (data not
shown).
Smaller epididymal fat pads and overall hepatosplenomegaly inGlmpgt/gt
mice
In spite of similar body weight, the Glmpgt/gt mice appeared leaner compared to the WT. Male
WT and Glmpgt/gt mice were sacrificed at the age of one and 4.5 months, and their epididymal
fat pads/body weight ratios were determined. As shown in Fig 2A and 2B, Glmpgt/gt mice had
significantly smaller epididymal fat pads compared to WT at the age of one month, with an in-
creased difference at 4.5 months of age. In contrast, the axillary and inguinal fat depots and the
interscapular brown adipose tissue were comparable betweent he genotypes (data not shown).
Next, we assessed the liver/body weight and spleen/body weight ratios in WT and Glmpgt/gt
mice. The Glmpgt/gt liver was significantly enlarged at 0.8, 1, 2, 4.5 and 7.5 months of age com-
pared to age-matched WT (Fig 2C), while Glmpgt/gt spleen was significantly enlarged at 1, 2,
3.5, 4.5, 6, 7.5 and 9 months of age compared to age-matched WT animals (Fig 2D).
Decreased blood glucose, serum lipids and increased liver
triacylglycerol (TAG) inGlmpgt/gtmice
Five months old Glmpgt/gt mice had significantly reduced levels of blood glucose compared to
WT mice when fed ad libitum (Fig 3A). Analysis of serum concentrations of triacylglycerol
(TAG) in WT and Glmpgt/gt mice aged 1–9 months, showed an overall level that was signifi-
cantly lower in the Glmpgt/gt mice (p< 0.001) (Fig 3B and 3C). A significant decrease was also
found for serum non-esterified fatty acids (NEFA) concentrations in Glmpgt/gt compared to
WT mice aged 1–9 months (p< 0.001) (Fig 3D and 3E). Liver content of TAG was measured
in 6 months old WT and Glmpgt/gt mice. As shown in Fig 3F, there were significantly higher
levels of liver TAG in Glmpgt/gt compared to WT mice.
Changes in expression of metabolic genes inGlmpgt/gt liver
Metabolic homeostasis is regulated by peroxisome proliferator-activated receptors (PPARs)
[24]. In livers from 3.5 months old mice, GLMP ablation resulted in altered mRNA expression
of the three PPAR isoforms. Fig 4A shows a decreased expression of Ppara and increased ex-
pression of Ppard and Pparg in Glmpgt/gt liver relative to WT animals. In contrast, the PPAR
co-regulator Pgc1a was not differently expressed between the two genotypes. Genes involved in
Fig 1. Loss of GLMP does not affect body weight gain and feed efficiency in youngmice. (A) Body weight gain for male WT andGlmpgt/gtmice were
monitored every week from 3 to 15 weeks of age, and then at 4.5, 6, 7.5 and 9 months of age. (B) The feed efficiencies of WT andGlmpgt/gtmice were
monitored from 4 to 14 weeks of age (n = 27–31) (*** p < 0.005 vs. WT). Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g001
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de novo lipogenesis (Fasn, Scd1 and Scd2) were found to be significantly upregulated in Glmpgt/gt
relative toWT liver (Fig 4B). The fatty acid transporter, Cd36 showed a 4.6-fold increased ex-
pression in Glmpgt/gt liver, while cytoplasmic fatty acid binding protein Fabp1 was significantly
decreased compared toWT (Fig 4C). The expression of the initiator of peroxisomal fatty acid
beta-oxidation, Acox1 was significantly decreased in Glmpgt/gt liver, while no differences were
found for the expression of Acox2 (Fig 4D). Genes involved in mitochondrial fatty acid beta-oxi-
dation (Cpt1a and Acadl) were not differently expressed between the two genotypes (Fig 4E).
Furthermore, the expression of the lipid droplet associated proteins perilipin 2 and 5 (Plin2 and
Plin5) was significantly decreased in Glmpgt/gt liver (Fig 4F). A decreased expression of a lipopro-
tein lipase regulator, Angptl4 was also detected in Glmpgt/gt liver, while the expression of Apoc3, a
very low-density lipoprotein (VLDL) regulatory protein, was increased compared toWT (Fig
4G). With regard to genes involved in glucose metabolism, a decreased expression of the glucose
transporter, Glut2 was detected in Glmpgt/gt liver compared toWT. No differences in expression
were detected for liver specific hexokinase (Gck), while the expression of Pdk4, an inhibitor of
pyruvate dehydrogenase complex, was significantly upregulated inGlmpgt/gt liver compared to
WT (Fig 4H).
Fig 2. GLMP ablation causes reduced size of epididymal fat pads and hepatosplenomegaly. (A) Representative pictures of epididymal fat pads and (B)
epididymal fat pads/body weight ratios in 1 (n = 4) and 4.5 months (n = 10–12) old WT andGlmpgt/gtmice. (C) Spleen/body weight ratios and (D) liver/body
weight ratios in WT andGlmpgt/gtmice were examined at designated time-points between 2 weeks and 9 months of age (n = 10–12) (* p < 0.05, ** p < 0.01,
*** p < 0.005 vs. WT). Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g002
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Altered glucose and fatty acid uptake and oxidation inGlmpgt/gt
hepatocytes
To assess whether GLMP ablation affects glucose and fatty acid metabolism in liver cells, hepa-
tocytes were isolated from 4–6 weeks old Glmpgt/gt and WTmouse liver and exposed to either
[14C]glucose or [14C]oleic acid (OA) for 4 h. Ablation of GLMP resulted in increased glucose
uptake (Fig 5A) and oxidation (Fig 5B) in Glmpgt/gt hepatocytes. Exposure to [14C]OA revealed
a significantly higher uptake of [14C]OA in Glmpgt/gt hepatocytes compared to WT cells (Fig
5C), while the oxidation capacity for OA was comparable between the two genotypes (Fig 5D).
To further explore metabolism of OA, we performed thin layer chromatography on cell cul-
ture media and cell homogenates after 4 h exposure to [14C]OA. No significant difference in se-
cretion of triacylglycerol (TAG) into the media could be detected (data not shown), but there
was a significant increase of accumulated total lipids in Glmpgt/gt hepatocytes compared to WT
hepatocytes (Fig 6A). This difference was primarily contributed to by a significant increase in
TAG accumulation (Fig 6B). Incorporation of labelled OA in other lipids assayed, diacylgly-
cerol (DAG) (Fig 6C), non-esterified fatty acids (NEFA) (Fig 6D), phospholipids (Fig 6E), and
cholesterol esters (CE) (Fig 6F) did not significantly differ between Glmpgt/gt and
WT hepatocytes.
Fig 3. Glmpgt/gtmice have reduced blood glucose and circulating lipids, but increased liver triacylglycerol accumulation. (A) Blood glucose was
analyzed in ad libitum fed 5 months old WT andGlmpgt/gtmice (n = 5). (B, C) The levels of circulating triacylglycerol (TAG) and (D, E) non-esterified fatty
acids (NEFA) in WT andGlmpgt/gtmice were analyzed at designated time-points between 1 and 9 months of age (n = 4–8). (F) Liver TAG content was
analyzed in 6 months old WT andGlmpgt/gt liver homogenates, and normalized to protein content (n = 6–7) (* p < 0.05, ** p < 0.01, *** p < 0.005 vs. WT).
Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g003
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Increased de novo lipogenesis inGlmpgt/gt hepatocytes
Primary hepatocytes fromWT and Glmpgt/gt mice were exposed to [14C]acetate for 4 h, and
thin layer chromatography was performed on cell homogenates in order to assess de novo lipo-
genesis. The levels of newly synthesized NEFA showed no significant difference between the
two genotypes (Fig 7A), but the incorporation into DAG was found to be significantly elevated
(Fig 7B). A clear tendency for increased synthesis of TAG was also observed for Glmpgt/gt
Fig 4. Altered expression of genes involved in metabolism inGlmpgt/gt liver. (A) qPCR analyses of 3.5 months old mouse livers from wild type (WT) and
Glmpgt/gtmice showed altered expression of genes involved in metabolic regulation (Pgc1a, Ppara, Ppard, Pparg), (B) lipogenesis (Fasn, Scd1, Scd2), (C, D,
E) lipid metabolism (Cd36, Fabp1, Acox1, Acox2, Cpt1a, Acadl) (F) lipid droplets (Plin2, Plin5), (G) very low-density lipoproteins (Angptl4, Apoc3) and (H)
glucose metabolism (Glut2,Gck, Pdk4) inGlmpgt/gt liver (n = 4–8, * p < 0.05, ** p < 0.01, *** p < 0.005 vs. WT). Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g004
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hepatocytes (Fig 7C), which, however, did not reach statistical significance. Higher incorporation
of labelled acetate into PL (Fig 7D) and CE (Fig 7E) was also detected in Glmpgt/gt hepatocytes.
Taken together, these results indicate increased lipogenesis in Glmpgt/gt hepatocytes compared to
WT cells, which was also reflected in the total amount of synthesized lipids (Fig 7F).
Fig 5. Glucose and oleic acid oxidation in WT andGlmpgt/gt hepatocytes.Overnight cultured primary hepatocytes fromWT andGlmpgt/gtmice were
incubated with [14C]glucose (0.6 μCi/mL, 200 μM) or [14C]oleic acid (OA) (0.5 μCi/mL, 100 μM) for 4 h. (A) Total [14C]glucose uptake, (B) [14C]glucose
oxidation, (C) [14C]OA uptake and (D) [14C]OA oxidation were measured. Substrate uptake was calculated as the sum of cell-associated radioactivity and
[14C]CO2 production. Substrate oxidation was measured as [
14C]CO2 production. Results were normalized to protein content (n = 20 experiments,
representing 4 individual mice/genotype, with 5 replicates each, * p < 0.05, *** p < 0.005 vs. WT). Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g005
Fig 6. Glmpgt/gt hepatocytes incorporate more [14C]oleic acid into triacylglycerol.Overnight cultured primary hepatocytes fromWT andGlmpgt/gtmice
were incubated with [14C]oleic acid (0.5 μCi/mL, 100 μM) for 4 h. (A) The total amount of cell accumulated lipids, (B) triacylglycerol (TAG), (C) diacylglycerol
(DAG), (D) non-esterified fatty acids (NEFA), (E) phospholipids and (E) cholesterol esters (CE) were analyzed using thin layer chromatography (n = 9
experiments, representing 3 individual mice/genotype, with 3 replicates each, ** p < 0.01 vs. WT). Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g006
GLMP Ablation Results in Metabolic Dysregulation in Liver
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Discussion
In this study, we showed that wild type (WT) and Glmpgt/gt mice initially had similar growth
rates. The feed efficiency was also comparable for the two genotypes up to the age of 14 weeks.
Yet the epididymal fat pads were significantly smaller in Glmpgt/gt siblings compared to WT
mice at both one and 4.5 months of age. Other fat depots such as the axillary and inguinal
white adipose tissue and the interscapular brown adipose tissue, however, were comparable be-
tween the genotypes. Hepatosplenomegaly contributed to the similar body weights until the
age of 9 months when the Glmpgt/gt siblings had significantly reduced body weight. The re-
duced sizes of the epididymal fat pads were reflected in lower levels of circulating triacylgly-
cerol (TAG) and non-esterified fatty acids (NEFA) in Glmpgt/gt mice. In addition, the Glmpgt/gt
mice had lower blood glucose concentration. Gene expression analysis using liver mRNA from
WT and Glmpgt/gt mice indicated changes in both glucose and lipid metabolic pathways, and
biochemical analysis of whole liver homogenates detected higher TAG levels in Glmpgt/gt liver.
Exposing isolated primary hepatocytes fromWT and Glmpgt/gt mice to radiolabelled oleic acid
(OA) showed that the Glmpgt/gt hepatocytes accumulated significantly more OA than WT he-
patocytes, and that the increased OA taken up was stored as TAG. Exposure to radiolabelled
Fig 7. Increased de novo lipogenesis inGlmpgt/gt hepatocytes.Overnight cultured primary hepatocytes fromWT andGlmpgt/gtmice were incubated with
[14C]acetate (0.5 μCi/mL, 100 μM) for 4 h. (A) The amount of synthesized non-esterified fatty acids (NEFA), (B) diacylglycerol (DAG), (C) triacylglycerol
(TAG), (D) phospholipids, (E) cholesterol esters (CE) and (F) total lipids were analyzed using thin layer chromatography (n = 8 experiments, representing 4
individual mice/genotype, with 2 replicates each, * p < 0.05 vs. WT). Values are presented as mean ± SEM.
doi:10.1371/journal.pone.0129402.g007
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glucose and acetate revealed a higher oxidation of glucose and increased de novo lipogenesis,
respectively, in Glmpgt/gt hepatocytes compared to WT cells.
In most lysosomal disorders, the primary lysosomal dysfunction induces secondary alter-
ations in other metabolic pathways [25], some of which may be adaptive changes in order to
provide metabolites for de novo synthesis of macromolecules, because lysosomal dysfunction
might inhibit adequate recycling of metabolites [14, 26]. As a consequence, reduced adiposity
and body weight, possibly caused by higher tissue demand for metabolites, has been observed
in several mouse models with lysosomal disorders [14, 26]. However, the body weight of youn-
ger Glmpgt/gt mice was comparable to that of their WT siblings since the reduced adiposity was
compensated by hepatosplenomegaly. Similar observations have been reported for the mouse
models for mucopolysaccharidosis (MPS) type I and IIIB [14]. Interestingly, as seen in the
Glmpgt/gt mouse, reduced adiposity, reduced blood glucose, reduced lipid levels and hepato-
megaly were also reported in these mice [14]. A similar feed efficiency between WT and
Glmpgt/gt mice suggested that the Glmpgt/gt mice did not suffer from malabsorption as was also
shown for mouse models with other lysosome deficiencies [14].
We have recently established that the Glmpgt/gt mice suffer from a mild chronic liver injury,
as indicated by the modest increase in serum transaminase levels. However, by the age of 6
months, the sustained liver injury led to a well-established fibrosis with increased inflammation
and oxidative stress [5], conditions known to disturb the liver's capacity for regulating glucose,
lipid and protein homeostasis [18]. As the liver is an important organ for glucose homeostasis
[27], the small decrease in resting blood glucose may be caused by increased glucose flow to the
liver. Somewhat conflicting studies have been reported regarding glucose uptake capacity in fi-
brotic liver, which has been ascribed to differences in experimental setup [28–32]. A recent
study using primary hepatocytes isolated from early, and advanced fibrotic rat livers, demon-
strated a gradual decrease in mitochondrial function [33], an established secondary effect of ad-
vanced liver fibrosis [34]. Hepatocytes from early fibrotic livers increased the glycolytic flux in
order to compensate for impaired ATP-production by oxidative phosphorylation [33]. Al-
though the ATP-production capacity of Glmpgt/gt mitochondria needs to be further elucidated,
we showed by using radiolabelled glucose that the Glmpgt/gt hepatocytes consumed significantly
higher levels of glucose compared to WT hepatocytes. Increased flow of glucose to the liver is
known to stimulate the expression of lipogenic genes [35]. By using radiolabelled acetate, we
showed that de novo lipogenesis was induced in Glmpgt/gt hepatocytes, an expected result given
the increased expression of lipogenic genes in Glmpgt/gt liver.
Unexpectedly, the expression of Pdk4 was significantly increased in Glmpgt/gt liver, suggest-
ing an inhibition of the pyruvate dehydrogenase complex, an event usually associated with in-
hibition of de novo lipogenesis and activation of gluconeogenesis [36]. An increase in Pdk4
expression has been reported in two independent mouse models of liver fibrosis, resulting
from chemical-induced liver damage [37] and chronic biliary injury [38]. Interestingly, the in-
creased Pdk4 expression in the chemical-induced model was not accompanied by increased ex-
pression of gluconeogenic genes [37]. Similarily, theMdr2-/- mouse liver (model for chronic
biliary injury [39]) had increased expression of lipogenic genes, and developed steatotic nod-
ules [38]. In both studies, the increased Pdk4 expression was explained as preventive adapta-
tions to the hepatic injury [37, 38]. Increased Pdk4 expression in the Glmpgt/gt liver is likely to
be an adaptive response to the chronic liver injury, although increased glucose flux through the
pentose phosphate pathway, which contributes to the antioxidant defense, and NADPH pro-
duction required for de novo lipogenesis [40] is also a possibility.
Abnormal accumulation of lipids in the liver is a known consequence of dysregulation of
metabolism [41]. However, in our initial report, histological analysis failed to reveal obvious
steatosis in Glmpgt/gt liver [5]. Here, using a biochemical approach, we showed that Glmpgt/gt
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mice accumulated slightly more liver TAG than WT animals. The small, relative difference
might be undetectable using histological methods. In support of the elevated TAG accumula-
tion in Glmpgt/gt liver, the increased expression of PPARγ as seen in the Glmpgt/gt liver is a hall-
mark of hepatic steatosis [42], as it stimulates expression of lipogenic genes [18, 43] and the
fatty acid transporter, CD36 [44]. Increased Cd36mRNA expression has been found to corre-
late with increased hepatic TAG content in different models of hepatic steatosis [45–47]. After
exposure to radiolabelled OA, an increased fatty acid uptake concomitant with increased stor-
age as TAG in Glmpgt/gt hepatocytes was observed, supporting the observed TAG accumulation
in Glmpgt/gt liver. Apart from increased fatty acid uptake by hepatocytes and de novo lipogene-
sis, compromised assembly and secretion of VLDL particles can contribute to lipid accumula-
tion [18, 41, 48, 49]. In our experimental setup, no significant decrease of TAG secretion was
detected for Glmpgt/gt hepatocytes. The increased expression of Apoc3, as detected in Glmpgt/gt
liver is probably a result of decreased PPARα expression and increased influx of glucose [50].
Apoc3 expression is usually positively correlated with plasma TAG levels [51, 52]. However,
ApoC3-containing lipoprotein secretion is stimulated by elevated levels of plasma NEFA [53],
which were decreased in Glmpgt/gt mice.
The detected liver steatosis in Glmpgt/gtmice may have been promoted by chronic inflamma-
tion [54, 55]. In our previous study, increased expression of inflammatory cytokines, including
tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) were detected in Glmpgt/gt liver [5].
Kupffer cells, activated by liver injury, have been shown to be essential for the development of
diet-induced hepatic steatosis in rats, as they alter metabolic pathways in hepatocytes through
TNFα secretion [56]. TNFα promotes the lipogenic inducer sterol regulatory element binding
protein-1c (SREBP1c) [57] and the protein expression of CD36 [58]. In addition, TNFα stimu-
lates lipolysis in peripheral adipose tissue to release free fatty acids into the circulation [59]. The
reduced adipose tissue size and reduced levels of circulating fatty acids observed in Glmpgt/gt
mice may be due to prolonged stimulation of adipose tissue lipolysis. Finally, activated Kupffer
cells secrete IL-1β, which downregulates the expression of PPARα [60], a positive regulator of
lipid catabolism [61].
The recent identification of a lysosomal nutrient sensing machinery (LYNUS) has provided
a direct link between intralysosomal nutrient levels and the expression of metabolic genes [62,
63]. In periods of nutrient scarcity, LYNUS releases the transcription factor EB into the nucleus
where it promotes the expression of genes involved in autophagy and lysosomal biogenesis, in
addition to genes involved in fatty acid β-oxidation through induced expression of PPARα and
PGC1α [63–65]. A significant decrease in Ppara expression was detected in Glmpgt/gt liver, and
we might hypothesize that ablation of the lysosomal membrane protein, GLMP, influences
normal LYNUS function, a secondary effect observed in many lysosomal disorders [11],
thus affecting normal Ppara expression and lipid turnover. Dysregulation of metabolism in
Glmpgt/gt liver might in turn affect adipose tissue. However, one of the limitations of the present
study is the inability to dismiss the metabolic alterations in Glmpgt/gt liver as secondary effects.
We are currently establishing a cell-type-specific transgenic mouse model in order to address
this question in future studies.
In summary, we showed that Glmpgt/gtmice have a similar body weight gain and feed effi-
ciency as WTmice until 9 months of age. Similar to some other mouse models with a dysfunc-
tional lysosomal protein, a reduced adiposity and an liver fibrosis were also detected in Glmpgt/gt
mice [5]. Analysis of serum glucose and lipid levels showed a significant decrease in Glmpgt/gt
mice. In addition to increased hepatic TAG content and changes in the expression of metabolic
genes in Glmpgt/gt liver, our data strongly indicate metabolic dysregulation in Glmpgt/gtmice.
Analysis using primary hepatocytes supported the findings in Glmpgt/gt liver, and showed en-
hanced uptake of fatty acids, increased de novo lipogenesis, and higher consumption of glucose
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in Glmpgt/gt hepatocytes. Ablation of the lysosomal membrane protein GLMP has recently been
shown to cause chronic liver injury in mice [5]. In this study, we demonstrated that metabolic
dysregulation is a likely contributor to the pathophysiology following GLMP ablation.
Supporting Information
S1 Fig. Verification of disrupted GLMP expression in Glmpgt/gt mice. Lysosome-enriched
fractions from mouse kidney and liver after tyloxapol treatment were used to verify the ablation
of GLMP expression in Glmpgt/gt mice. LAMP1 served as loading control.
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